pancreatitis and glp-1 Reconciling GLP-1s Pancreatitis Warnings Strengthened on GLP-1RAs

Fortunately, these side effects typically improve over time as your body adjusts to the medication

Warning Letters to Telehealth providers marketing GLP-1 compounded On March 3rd, FDA sent multiple sets of warnings to 30 Telehealth companies offering GLP-1s on their websites warning them to refrain from improperly using a brand when they are not the compounder or claiming equivalency to FDA approved drugs

The active pharmaceutical ingredients (semaglutide and tirzepatide) are based on FDA-approved compounds, but compounded formulations operate under the 503A regulatory pathway that allows pharmacies to customize medications for individual patients

R.et al (2012)

In response, semaglutide and tirzepatide were added to the FDA Drug Shortages Database, allowing compounding pharmacies to produce generic versions

Ask your doctor about the signs and symptoms of hypoglycemia, how to monitor your blood sugar, and what to do if you have a hypoglycemic event